Merck & Co., Inc. (NYSE:MRK) Stock Position Boosted by Cutler Capital Management LLC

Cutler Capital Management LLC boosted its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 0.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,478 shares of the company’s stock after buying an additional 287 shares during the quarter. Merck & Co., Inc. makes up about 3.0% of Cutler Capital Management LLC’s holdings, making the stock its 6th largest position. Cutler Capital Management LLC’s holdings in Merck & Co., Inc. were worth $7,138,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of MRK. Burkett Financial Services LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Bare Financial Services Inc purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Rakuten Securities Inc. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $30,000. RIA Advisory Group LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $30,000. Finally, Tidemark LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK stock traded up $0.15 during midday trading on Friday, reaching $130.67. 4,945,599 shares of the company traded hands, compared to its average volume of 7,277,381. The firm’s 50 day simple moving average is $128.51 and its two-hundred day simple moving average is $121.34. Merck & Co., Inc. has a 1-year low of $99.14 and a 1-year high of $133.10. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.25 and a quick ratio of 0.99. The firm has a market cap of $330.96 billion, a PE ratio of 145.18, a price-to-earnings-growth ratio of 2.52 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. During the same period last year, the firm earned $1.40 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts expect that Merck & Co., Inc. will post 8.64 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 8th. Stockholders of record on Monday, June 17th will be given a dividend of $0.77 per share. The ex-dividend date is Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.36%. Merck & Co., Inc.’s payout ratio is 342.22%.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MRK. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Truist Financial raised their price target on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a report on Tuesday. Finally, TheStreet downgraded shares of Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

View Our Latest Research Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.